Price target
386.500.000.00%
The 24 analysts offering 1 year price forecasts for VX1 have a max estimate of — and a min estimate of —.
Analyst rating
Based on 34 analysts giving stock ratings to VX1 in the past 3 months.
EPS
Reported
Estimate
Reported
Estimate
Surprise
Revenue
Reported
Estimate
Reported
Estimate
Surprise
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
VX1 EPS for the last quarter is 3.59 CHF despite the estimation of 3.39 CHF. In the next quarter EPS is expected to reach 3.64 CHF. Track more of Vertex Pharmaceuticals Incorporated financials and stay on top of what is up with the company.
In the next quarter Vertex Pharmaceuticals Incorporated revenue is expected to reach 2.42 B CHF. Check out Vertex Pharmaceuticals Incorporated revenue and earnings and make informed decisions.
According to analysts, VX1 price target is 386.50 CHF with a max estimate of 497.49 CHF and a min estimate of 263.09 CHF. Check if this forecast comes true in a year, meanwhile watch Vertex Pharmaceuticals Incorporated stock price chart and keep track of the current situation with VX1 news and stock market news.
We've gathered opinions of 34 analysts rating VX1 stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as buy. Note that it's not a trading advice — your own analysis is still required.